Skip to main content
OpenTrials
Completed

NCT Number: NCT02207114

Using Biomarkers to Optimize Antibiotic Strategies in Sepsis

The proposed work will provide critical insights into the potential impact of a biomarker-based algorithm on reducing unnecessary antibiotic use in different adult and pediatric/neonatal ICU's. This proposal will also assess the costs (or savings) of a biomarker-based intervention. Overall, the results of this work will be critical in informing future strategies to eliminate unnecessary antibiotic use and curb the continued rise in antimicrobial resistance.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital of the University of Pennsylvania - Medical Intensive Care Unit

Philadelphia, Pennsylvania, 19104, United States

About this study

The goal of this project is reduce unnecessary use of antibiotics in the ICU. The purpose of Phase I of the study is to identify the biomarker, or combination of biomarkers, that provides optimal test characteristics in identifying adults and children/neonates with presumed sepsis who have a very low likelihood of bacterial infection. Results of Phase I will result in development of a biomarker-based algorithm to inform need for antibiotic use in ICU patients. In Phase II, the impact of this biomarker-based algorithm on reducing antibiotic use in the ICU will be determined. Costs or savings associated with the algorithm will also be assessed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • SIRS Criteria

SIRS is considered to be present when patients have more than one of the following clinical findings:

  • body temperature >38°C or <36°C
  • heart rate >90 min-1
  • respiratory rate of >20 min-1 or a Paco2 of <32 mm Hg
  • and a white blood cell count of >12,000 cells µL-1 or <4,000 µL-1
  • new empiric antibiotic therapy is initiated, indicating the suspicion of infection. Accepted criteria for SIRS will be used for the Medical Intensive Care Unit and Surgical Intensive Care Unit populations, with appropriate age-specific vital signs definitions to help make the definitions relevant for the Pediatric Intensive Care Unit population.

Exclusion criteria

  • a code status of "do not resuscitate"
  • absence of initiation or expansion of antibiotic therapy despite meeting criteria for sepsis
  • presence of an immunocompromising condition.

An immunocompromising condition will be defined as one of the following:

  • human immunodeficiency virus (HIV) infection with a t-helper cell (CD4) count <200 cell/mm3; 2) immunosuppressive therapy after organ transplantation
  • neutropenia (<500 neutrophils/mm3)
  • active chemotherapy within the 3 months preceding eligibility or
  • diagnosis of cystic fibrosis.

These criteria all represent conditions in which antibiotic use is much less likely to be decreased regardless of the results of a biomarker and are consistent with exclusion criteria used in past studies of the impact of biomarkers.

Treatment and study plan

Biomarker Algorithm Intervention

Other

The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.

Primary outcomes

  1. Duration of antibiotic therapy started upon enrollment for presumed sepsis

    Time frame: Two years

    The primary outcome is the duration of antibiotic treatment after enrollment, expressed in days. This variable will focus specifically on the antibiotic agents given for the episode of presumed sepsis for which the patient was included in the study.

Secondary outcomes

  1. Subject's Final Disposition

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 6 days

    This includes assessing ICU mortality, hospital mortality, or hospital discharge as an ultimate outcome.

Other outcomes

  1. Length of stay

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 6 days

    A secondary outcome of length of stay both in the Intensive Care Unit as well as total hospital stay after enrollment will be assessed.

  2. Clinical Cure

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 6 days

    This secondary outcome measure is defined as resolution of sepsis. Clinical signs and symptoms present at the time of enrollment as well as the presence in any clinical cultures of antimicrobial resistant organisms not present prior to enrollment will be ascertained.

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Official study title

Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network - Randomized Control Trial

Important dates

Study start
2012
Primary completion
2016
Study completion
2023
First posted
Aug 1, 2014
Registry last updated
Jan 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.